Larimar Therapeutics (LRMR) Cash from Financing Activities (2013 - 2024)
Larimar Therapeutics' (LRMR) quarterly Cash from Financing Activities came in at $36000.0 in Q4 2024, up 20.0% quarter-over-quarter from $30000.0 in Q3 2024.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Cash from Financing Activities (2013 - 2024) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Cash from Financing Activities for 10 consecutive years, with $36000.0 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Cash from Financing Activities changed N/A year-over-year to $36000.0; the trailing twelve-month figure through Dec 2024 stood at $161.9 million (up 218860.81% YoY), and the FY2025 full-year result was $65.1 million, down 59.79% from the prior year.
- Cash from Financing Activities rose to $36000.0 in Q4 2024 per LRMR's latest filing, from $30000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $162.2 million in Q1 2024 and bottomed at -$334000.0 in Q2 2024.
- Historically, Cash from Financing Activities has averaged $28.4 million across 3 years, with a median of $36000.0 in 2024.
- The widest YoY moves for Cash from Financing Activities: up 9981.05% in 2020, down 101.36% in 2020.
- Over 3 years, Cash from Financing Activities stood at $242000.0 in 2020, then tumbled by 230.58% to -$316000.0 in 2022, then soared by 111.39% to $36000.0 in 2024.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $36000.0, $30000.0, and -$334000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 36,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Jun 30, 2024 | -334,000.00 |
| Mar 31, 2024 | 162.15 Mn |
| Dec 31, 2022 | -316,000.00 |
| Dec 31, 2020 | 242,000.00 |
| Sep 30, 2020 | -135,000.00 |
| Jun 30, 2020 | 83.90 Mn |
| Mar 31, 2020 | 9.58 Mn |
| Dec 31, 2019 | 3.46 Mn |
| Sep 30, 2019 | 9.95 Mn |
| Jun 30, 2019 | 5.90 Mn |
| Mar 31, 2019 | 95,000.00 |
| Dec 31, 2018 | 1.76 Mn |
| Sep 30, 2018 | 64.91 Mn |
| Jun 30, 2018 | -18,000.00 |
| Mar 31, 2018 | 261,000.00 |
| Dec 31, 2017 | 18.73 Mn |
| Sep 30, 2017 | -724,000.00 |
| Jun 30, 2017 | -712,000.00 |